BCTXF - BriaCell Therapeutics Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0328
+0.0042 (+14.69%)
At close: 2:59PM EST
Stock chart is not supported by your current browser
Previous Close0.0286
Open0.0225
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0225 - 0.0330
52 Week Range0.0225 - 38.0700
Volume292,464
Avg. Volume24,988
Market Cap22,245
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0310
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    BriaCell Completes Share Consolidation

    BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 02, 2020 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage.

  • GlobeNewswire

    BriaCell Therapeutics Corp. Announces Share Consolidation

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that its Board of Directors has approved a consolidation (the "Consolidation") of the Company's issued and outstanding common shares (the "Common Shares") on the basis of three hundred (300) pre-consolidation shares for one (1) post-consolidated share. The purpose of the Consolidation is to facilitate the Company’s ability to list on a recognized stock exchange in the United States of America.

  • GlobeNewswire

    BriaCell to Present at Biotech Showcase™ 2020 in San Francisco

    BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 17, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.

  • GlobeNewswire

    BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®

    Continued additive or synergistic activity observed in combination study of Bria-IMT™ with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.) as evident by tumor shrinkage even in the absence of “HLA Matching”. BERKELEY, Calif., and VANCOUVER, British Columbia, Dec. 13, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce the presentation results of clinical studies with its lead product candidate,  Bria-IMT™,  summarized in two poster sessions during the 2019 San Antonio Breast Cancer Symposium® (SABCS). The December 12th poster summarized data of the Bria-IMT™ monotherapy study and the ongoing Phase I/IIa clinical study of Bria-IMT™ in combination with immune checkpoint inhibitors including pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.), and more recently, Incyte’s INCMGA00012, in advanced breast cancer.

  • GlobeNewswire

    BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th

    Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: Bria-IMT™ in.

  • GlobeNewswire

    BriaCell Announces Voting Results of the Special Meeting of Shareholders

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all matters addressed at the special meeting (the "Meeting") of the holders of common shares (the "Common Shares") in the capital of BriaCell held on October 22, 2019. At the Meeting, shareholders approved an ordinary resolution without variation providing the board of directors of the Company (the "Board") discretion to consolidate the Company's issued and outstanding Common Shares at a consolidation ratio of up to three-hundred (300) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the "Consolidation") or such lower ratio as the Board may determine (the "Consolidation Resolution").

  • GlobeNewswire

    BriaCell Announces Closing of Non-Brokered Private Placement of $568,444

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has closed its previously-announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company. Under the Offering, the Company issued a total of 8,120,633  common shares at a price of C$0.07 per common share for gross proceeds of C$568,444.

  • GlobeNewswire

    BriaCell Therapeutics Corp. to File Amendment to Management Information Circular

    BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed on SEDAR an amendment to its management information circular dated September 23, 2019 (the "Circular") to amend the maximum share consolidation ratio from 100:1 to 300:1 (the "Amendment"). BriaCell’s Board of Directors retains the discretion to fix the ratio and determine the timing for implementation of the share consolidation.  As indicated in the Circular, BriaCell is considering applying for listing on a recognized US stock exchange.  The conditions to any such listing would include the common shares trading at a minimum prescribed price and would, based on current trading values, require a significant share consolidation.

  • GlobeNewswire

    BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer

    Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell’s lead candidate, Bria-IMT™ in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer. Cancer blocks the immune system preventing it from fighting and destroying cancer cells. Bria-IMT™ activates the immune system to fight and eliminate the cancer cells.

  • GlobeNewswire

    BriaCell Therapeutics Corp. to Clarify Record Date

    BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announced on August 23, 2019 that it will hold a special meeting of shareholders on October 22, 2019 (the "Meeting"). The Company would like to clarify that September 18, 2019 was the record date for determining shareholders of the Company entitled to receive notice of, and to vote at, the Meeting being held on October 22, 2019 in Toronto. The Company inadvertently advertised September 20, 2019 as the record date in its management information circular, dated September 23, 2019, for the upcoming Meeting.

  • GlobeNewswire

    Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month

    BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 01, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage.

  • GlobeNewswire

    BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced the addition of immunology expert, Cara L. Haymaker, Ph.D., to its Scientific Advisory Board, effective immediately. Additionally, Dr. Bill Williams, BriaCell’s President & CEO, has been selected to lead the upcoming special joint issue of the prestigious, peer-reviewed journals, Frontiers in Pharmacology and Frontiers in Oncology with the research topic of 'Targeted Immunotherapy for Cancer'. Dr. Cara Haymaker is an assistant professor at Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center.

  • GlobeNewswire

    BriaCell Announces Private Placement of up to $600,000

    BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce a non-brokered private placement (the “Private Placement”) of up to approximately 8,571,428 common shares in the capital of the Company for gross proceeds of up to approximately C$600,000 at a price per common share of C$0.07. The closing of the Offering is scheduled to occur on or about September 26, 2019.  All securities issued under the Private Placement will be subject to a hold period expiring 4 months plus 1 day following the closing date of the Private Placement.

  • GlobeNewswire

    BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®

    Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress.  Publicly-traded securities of BriaCell Therapeutics Corp. (BCT.V) (BCTXF) will remain halted for the duration of CEO Dr. Williams’ presentation. Robust responder experienced a highly remarkable reduction in breast cancer tumors in the adrenal gland and the outer lining of the brain – tumors that had metastasized to areas outside of her breasts. Prior to the Combination Study of Bria-IMT™ with KEYTRUDA®, she had failed prior regimens with 16 agents (13 chemotherapy and 3 hormonal).

  • GlobeNewswire

    BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia

    BERKELEY, Calif., Sept. 16, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in.

  • GlobeNewswire

    BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has upsized and closed its previously-announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company. Under the Offering, the Company issued a total of 12,090,007 common shares at a price of C$0.07 per common share for gross proceeds of C$846,300.49.

  • GlobeNewswire

    BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced it will be featured as a presenting company at the 21st Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City. If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference.

  • GlobeNewswire

    BriaCell Appoints Richard J. Berman to Board of Directors

    BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.

  • GlobeNewswire

    BriaCell Announces $350,000 Equity Investment by Board of Directors

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it intends to complete a non-brokered private placement of up to 5,000,000 common shares of the Company at a price of C$0.07 per common share for gross proceeds of up to approximately C$350,000 (the “Offering”).

  • GlobeNewswire

    BriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that BriaCell’s clinical findings were published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings, a supplement to the Journal of Clinical Oncology. ASCO’s Annual Meeting, taking place May 31-June 4, 2019 at the McCormick Place Convention Center in Chicago, IL, represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology.

  • GlobeNewswire

    BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all matters addressed at the annual and special meeting (the "Meeting") of the holders of common shares of BriaCell held on April 24, 2019.

  • GlobeNewswire

    BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that BriaCell’s clinical findings will be published in the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings, a supplement to the Journal of Clinical Oncology. ASCO’s Annual Meeting, taking place May 31-June 4, 2019 at the McCormick Place Convention Center in Chicago, IL, represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology.

  • GlobeNewswire

    BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity

    As presented at the American Association for Cancer Research (AACR) annual meeting:  early efficacy data for the first six advanced breast cancer patients dosed with Bria-IMT™ in combination with KEYTRUDA® suggest additive or synergistic effects on tumor regression (“shrinkage”). Findings support BriaCell’s hypothesis:  KEYTRUDA® acts by "awakening" a component of the immune system, while Bria-IMT™ "puts the foot on the gas" of the immune system, leading to more powerful anti-tumor activity. The combination with KEYTRUDA® appears to overcome the limitation of requiring patients to have an HLA match with Bria-IMT™.

  • GlobeNewswire

    BriaCell Announces Clinical Trial Collaboration Agreement with Incyte

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced a clinical trial collaboration and supply agreement (the “Agreement”) with Incyte  (INCY), a global biopharmaceutical company focused on discovering and developing novel therapeutics in oncology and other serious diseases. The Agreement is focused on, but not limited to, the selection of novel combinations for the treatment of advanced breast cancer along with a planned clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s selected compounds for advanced breast cancer.

  • GlobeNewswire

    BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million

    BERKELEY, Calif., and VANCOUVER, British Columbia, April 01, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.